Pharmaceuticals

STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal

SINGAPORE and MELBOURNE, Australia, Oct. 14, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients inAustralia, New Zealand and throughout SE Asia. Under the ...

2019-10-14 14:00 203

Admedus Inks $A36.2M Deal for CardioCel And VascuCel Patch Business

Transaction Highlights: * Admedus has sold the distribution rights to its CardioCel® and VascuCel® product range for$A36.2 million (including all earnouts) to LeMaitre Vascular Inc. * $A22.8M upfront payment plus two instalments of $A1m each after 12 months and 36 months * Up to $A11.4M on...

2019-10-14 12:51 308

CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership

* The new partnership will combine the research and development ingenuity of BJ Bioscience with the state-of-art biologics manufacturing set up of CMAB * CMAB will provide full development and manufacturing services for BJ Bioscience's BJ-005 bi-functional antibody * BJ-005 is planned to ent...

2019-10-11 18:00 1270

Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.

SHANGHAI, Oct. 11, 2019 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted inthe United States. This randomized, double-blind, placebo-controlled study evaluated the...

2019-10-11 13:00 270

Bayer G4A Partners With Wellthy Therapeutics

MUMBAI, India, Oct. 11, 2019 /PRNewswire/ -- Wellthy Therapeutics, South Asia's leading digital therapeutics (DTx) company today announced its partnership with Bayer (BAYN: DE) through its G4A partnership initiative. Wellthy Therapeutics stands out as onefrom over 750 digital health companies spr...

2019-10-11 09:00 664

MabPlex Lauded by Frost & Sullivan for Global Expansion of ADC Contract Manufacturing Services

YANTAI, China, Oct. 10, 2019 /PRNewswire/ -- Based on its recent analysis of the global antibody drug conjugate (ADC) contract manufacturing services market, Frost & Sullivan recognizesChina-based MabPlex International, Ltd (MabPlex) with the 2019 Global Growth Excellence Leadership Award. MabPle...

2019-10-10 21:00 409

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

SUZHOU, China and LONDON, Oct. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) and Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent's Ty...

2019-10-10 15:55 449

CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million

HONG KONG and NANJING, China, Oct. 9, 2019 /PRNewswire/ -- Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceu...

2019-10-09 20:58 451

Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ -- - RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments; - Objective Response and Disease Control Comparable to or better than most Immunotherapy opti...

2019-10-09 17:56 743

World Thrombosis Day Empowers People Around the World to Recognize and Help Prevent Life-Threatening Blood Clots

In Its Sixth Year, the Global Campaign Highlights Ways to Reduce the Impact of a Condition that Contributes to One in Four Deaths Worldwide CHAPEL HILL, North Carolina, Oct. 9, 2019 /PRNewswire/ -- On October 13, the World Thrombosis Day campaign shares an important message: patients, regardless ...

2019-10-09 12:00 303

Tim Oldham Appointed as Chief Executive Officer of AdAlta Ltd

* Experienced Pharmaceutical Executive * Decades of global business development, strategy and biologic drug development experience * Expertise to drive the next phase of AdAlta's growth MELBOURNE, Australia, Oct. 9, 2019 /PRNewswire/ -- The Board of AdAlta Limited (ASX:1AD), is pleased to a...

2019-10-09 09:42 476

Breast Cancer: Hormone Therapy Has a Bigger Impact Than Chemotherapy on Women's Quality of Life - Research by Institut Gustave Roussy

PARIS, Oct. 9, 2019 /PRNewswire/ -- Analysis of the CANTO cohort published in the journalAnnals of Oncology will upset received wisdom on the effects that hormone therapy and chemotherapy have on the quality of life in women with breast cancer. Contrary to ...

2019-10-09 07:00 305

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

SHENZHEN, China, Oct. 8, 2019 /PRNewswire/ -- Chipscreen Biosciences Co., Ltd. (Chipscreen, Stock Symbol: 688321.SH) and Novogene Co., Ltd. (Novogene) recently announced a strategic partnership for companion diagnostics (CDx) development. Under the agreement, Novogene will develop a CDx for Chips...

2019-10-08 20:46 397

Drugstore Chain Mik Japan Launches International "Samurai Drugstore" Online Store with USD 100,000 Point-Back Campaign

OSAKA, Japan, Oct. 8, 2019 /PRNewswire/ -- Established 48 years ago in Japan, Mik Japan Co., Ltd. (Head office:Osaka, Japan. President: Eiji Usui), a drugstore chain managing over 50 outlets, has opened Samurai Drugstore, an international online store for drugstore products fromJapan. The company...

2019-10-08 14:00 333

Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer

HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...

2019-10-08 08:00 433

Innovent Biologics Announces a New Placement Raised HK$2,351.33 Million

SUZHOU, China, Oct. 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announc...

2019-10-04 16:11 753

I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5

SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced that its I...

2019-10-04 13:40 428

Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine

QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...

2019-10-03 06:30 373

Successful implementation of ClinSpark® at Phase I unit of a Top-10 Biopharmaceutical company

GRAFTON, Wisconsin, Oct. 2, 2019 /PRNewswire/ -- Following the successful implementation of ClinSpark® at the Phase I unit of a top-10 biopharmaceutical company inEurope, the first study database was locked where the entire trial was conducted within the system. FDA submission-ready eCRFs of all ...

2019-10-02 23:37 312

Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US

ADELAIDE, Australia, Oct. 2, 2019 * Mayne Pharma Group Limited (Mayne Pharma or Company) (ASX: MYX) has signed a 20‑year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise a novel oral contraceptive comprising Estetrol (E4), and drospirenone, (E4/...

2019-10-02 12:01 7511
12345 ... 96